



Engineering Aptamers for Biomedical Applications II

Guest Editors:

Dr. Vittorio de Franciscis

Istituto per l'Endocrinologia e
Oncologia Sperimentale "G.
Salvatore", Via Tommaso De
Amicis 95 Via S. Pansini 5, 80145
Naples, Italy

Dr. Anna Kichkailo

Laboratory for Digital Controlled
Drugs and Theranostics, Federal
Research Center "Krasnoyarsk
Science Center of the Siberian
Branch of the Russian Academy
of Science", Akademgorodok 50,
660036 Krasnoyarsk, Russia

Deadline for manuscript
submissions:

closed (15 February 2021)

Message from the Guest Editors

Dear Colleagues,

This Special Issue, "Engineering Aptamers for Biomedical Applications II", will mainly focus on the more recent advances in the development of highly stable and specific aptamers suitable as therapeutic and diagnostic agents.

The introduction of modifications in the nucleic acids backbone, the expansion of genetic variability in nucleobases, and the generation of enzymes able to catalyze the synthesis of modified aptamers is revealing as invaluable advantage in the design of aptamer ligands in biomedicine. Aptamers obtained with nucleic acid variants exhibit high stability in circulating fluids, target binding affinity, and specificity, thus potentially improving their applicability as therapeutics and/or as diagnostic tools.

We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)